Abstract
Background In patients experiencing out-of-hospital cardiac arrest, optimization of oxygen delivery during cardiopulmonary resuscitation is a critical. Although both positive end-expiratory pressure (PEEP) and zero end-expiratory pressure (ZEEP) are employed during CPR, their respective impacts on clinically relevant outcomes is yet to be clearly established.
Methods This investigator-initiated, pragmatic, registry-based, multicenter, triple-blind randomized controlled superiority trial evaluates whether applying 8 cm H2O PEEP during cardiopulmonary resuscitation improves outcomes compared with ZEEP in adults with non-traumatic, non-drowning out-of-hospital cardiac arrest. Pre-randomized CPR kits (1:1 PEEP vs. sham) were used by ambulance sites during manual ventilation throughout the resuscitation process. The primary analysis was conducted in the principal stratum of patients who received either a supraglottic airway or endotracheal tube. The primary outcome was neurological status at hospital discharge measured by a utility-weighted score on the modified Rankin Scale. Secondary outcomes included prehospital return of spontaneous circulation, 30-day survival, and 6-month quality of life. The primary safety outcome was clinically significant pneumothorax.
Results Among the 3,200 patients who underwent randomization, 1,200 in the PEEP group and 1,200 in the ZEEP group were included in the principal stratum analysis. The mean utility-weighted modified Rankin Scale score at discharge was 0.1020 in the PEEP group and 0.1075 in the ZEEP group (mean difference corrected for covariates in a regression model of 0.0050; 95% CI -0.0159 - 0.0258). The observed rates in the PEEP and ZEEP groups of prehospital return of spontaneous circulation were X% vs. Y%; adjusted odds ratio, Z; 95% CI, A–B and in 30-day survival X% vs. Y%; adjusted odds ratio, Z; 95% CI, A–B. The incidence of clinically significant pneumothorax was similar between the PEEP and ZEEP groups, occurring in X% and Y% of patients, respectively (adjusted odds ratio, Z; 95% CI, A–B).
Conclusion Conclusion and discussion follow at Stage-2.
Stage-1 Registered Report We present our Stage-1 Registered Report as a full clinical trial article with all methods in past tense and including mock results, table and figures for the primary analysis. To remind the reader that this Stage-1 article is written before data collection, we highlight in color that these mock results are only for illustrative purposes and will be replaced by the actual results in the Stage-2 Registered Report.
Supplements All study supplements and updates are available in the ResearchEquals collection [1], including the protocol Version 2.1 (February 4, 2026) [2], DSMB charter [3] and example DSMB closed session report (based on mock data) [4], as well as an Excel sheet [5] and R code [6] used to generate Figure A.6.
Simultaneous evaluation PCI-RR and ethics The institutional review board1 tasked with the ethical evaluation of the REVIVE-PEEP trial agreed to perform a pilot experiment of simultaneous ethical and Stage-1 peer review at Peer Community In Registered Reports (PCI-RR). This means that all feedback will be considered as one round of review and the author’s reply to both will weigh the two sources of feedback together. The protocol Version 2.1 (February 4, 2026) [2] supplementing this manuscript is the version pre-ethical review and will be updated to a post-ethical review version after in-principle acceptance at PCI-RR. We will evaluate this pilot of simultaneous review as a major step towards ‘Trinity review’ aiming to reduce ‘redundant paperwork of three different documents — research papers, ethics review applications, and research grant applications — for the same research plan’[7].
Registration The REVIVE-PEEP trial will be registered in an registry part of the International Clinical Trials Registry Platform after ethics approval and PCI-RR in-principle acceptance, with this Stage-1 registered report serving as the full preregistration alongside the protocol; currently Version 2.1 (February 4, 2026) [2].
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NL-OMON61400
Clinical Protocols
https://doi.org/10.64898/2026.02.26.26346617
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Amsterdam UMC (METC NedMec+) gave ethical approval (July 22, 2026) for this work under identification number (Onderzoeksportaal ID) NL-009273: https://onderzoekmetmensen.nl/nl/trial/61400
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced will be made available in the Replication package (for reproducibility and replication) at ResearchEquals: https://doi.org/10.53962/p8t5-wzwr





